Literature DB >> 9849787

Demonstration of safety of probiotics -- a review.

S Salminen1, A von Wright, L Morelli, P Marteau, D Brassart, W M de Vos, R Fondén, M Saxelin, K Collins, G Mogensen, S E Birkeland, T Mattila-Sandholm.   

Abstract

Probiotics are commonly defined as viable microorganisms (bacteria or yeasts) that exhibit a beneficial effect on the health of the host when they are ingested. They are used in foods, especially in fermented dairy products, but also in pharmaceutical preparations. The development of new probiotic strains aims at more active beneficial organisms. In the case of novel microorganisms and modified organisms the question of their safety and the risk to benefit ratio have to be assessed. Lactic acid bacteria (LAB) in foods have a long history of safe use. Members of the genera Lactococcus and Lactobacillus are most commonly given generally-recognised-as-safe (GRAS) status whilst members of the genera Streptococcus and Enterococcus and some other genera of LAB contain some opportunistic pathogens. Lactic acid bacteria are intrinsically resistant to many antibiotics. In many cases resistances are not, however, transmissible, and the species are also sensitive to many clinically used antibiotics even in the case of a lactic acid bacteria- associated opportunistic infection. Therefore no particular safety concern is associated with intrinsic type of resistance. Plasmid-associated antibiotic resistance, which occasionally occurs, is another matter because of the possibility of the resistance spreading to other, more harmful species and genera. The transmissible enterococcal resistance against glycopeptide antibiotics (vancomycin and teicoplanin) is particularly noteworthy, as vancomycin is one of the last effective antibiotics left in the treatment of certain multidrug-resistant pathogens. New species and more specific strains of probiotic bacteria are constantly identified. Prior to incorporating new strains into products their efficacy should be carefully assessed, and a case by case evaluation as to whether they share the safety status of traditional food-grade organisms should be made. The current documentation of adverse effects in the literature is reviewed. Future recommendations for the safety of already existing and new probiotics will be given.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9849787     DOI: 10.1016/s0168-1605(98)00128-7

Source DB:  PubMed          Journal:  Int J Food Microbiol        ISSN: 0168-1605            Impact factor:   5.277


  104 in total

1.  Probiotic Therapy and Functional Foods for Prevention of Urinary Tract Infections: State of the Art and Science.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.725

Review 2.  Probiotics: a role in the treatment of intestinal infection and inflammation?

Authors:  E Isolauri; P V Kirjavainen; S Salminen
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

3.  In vitro adhesion and platelet aggregation properties of bacteremia-associated lactobacilli.

Authors:  P V Kirjavainen; E M Tuomola; R G Crittenden; A C Ouwehand; D W Harty; L F Morris; H Rautelin; M J Playne; D C Donohue; S J Salminen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  A potent probiotic strain from cheddar cheese.

Authors:  P Shobharani; Renu Agrawal
Journal:  Indian J Microbiol       Date:  2011-01-29       Impact factor: 2.461

5.  Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation.

Authors:  John C Lieske; William J Tremaine; Claudio De Simone; Helen M O'Connor; Xujian Li; Eric J Bergstralh; David S Goldfarb
Journal:  Kidney Int       Date:  2010-08-25       Impact factor: 10.612

6.  Development and application of a method for counterselectable in-frame deletion in Clostridium perfringens.

Authors:  Hirofumi Nariya; Shigeru Miyata; Motoo Suzuki; Eiji Tamai; Akinobu Okabe
Journal:  Appl Environ Microbiol       Date:  2010-12-23       Impact factor: 4.792

7.  Treating C. difficile.

Authors:  Bradley C Johnston; Sunita Vohra
Journal:  CMAJ       Date:  2005-02-15       Impact factor: 8.262

8.  Novel surface display system for proteins on non-genetically modified gram-positive bacteria.

Authors:  Tjibbe Bosma; Rolf Kanninga; Jolanda Neef; Sandrine A L Audouy; Maarten L van Roosmalen; Anton Steen; Girbe Buist; Jan Kok; Oscar P Kuipers; George Robillard; Kees Leenhouts
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

9.  Effects of strains of Lactococcus lactis on the production of nitric oxide and cytokines in murine macrophages.

Authors:  Chise Suzuki; Ayako Aoki-Yoshida; Hiromi Kimoto-Nira; Miho Kobayashi; Keisuke Sasaki; Koko Mizumachi
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

Review 10.  Probiotics for preterm infants?

Authors:  M Millar; M Wilks; K Costeloe
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-09       Impact factor: 5.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.